BRPI0418010A - derivados da cobalamina úteis para diagnóstico e tratamento de proliferação celular anormal - Google Patents
derivados da cobalamina úteis para diagnóstico e tratamento de proliferação celular anormalInfo
- Publication number
- BRPI0418010A BRPI0418010A BRPI0418010-0A BRPI0418010A BRPI0418010A BR PI0418010 A BRPI0418010 A BR PI0418010A BR PI0418010 A BRPI0418010 A BR PI0418010A BR PI0418010 A BRPI0418010 A BR PI0418010A
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosis
- vitamin
- cobalamin
- present
- cell proliferation
- Prior art date
Links
- 150000001867 cobalamins Chemical class 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 3
- 230000001613 neoplastic effect Effects 0.000 abstract 3
- 239000011715 vitamin B12 Substances 0.000 abstract 3
- 235000019163 vitamin B12 Nutrition 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 2
- 239000000032 diagnostic agent Substances 0.000 abstract 2
- 229940039227 diagnostic agent Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 102000011409 Transcobalamins Human genes 0.000 abstract 1
- 108010023603 Transcobalamins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
"DERIVADOS DA COBALAMINA úTEIS PARA DIAGNóSTICO E TRATAMENTO DE PROLIFERAçãO CELULAR ANORMAL". A presente invenção relaciona-se a derivados da cobalamina (a) que não possuem nenhuma afinidade de ligação ou que possuem uma baixa afinidade de ligação à proteína de transporte transcobalamina II (TCII) e (b) que conservam a atividade de substitutos da vitamina B12, opcionalmente transportando um agente terapêutico e/ou de diagnóstico, como um metal radioativo. Esses compostos possuindo uma taxa de acúmulo muito reduzida no sangue e em órgãos benignos, como rim e fígado, em comparação com a taxa de acúmulo em tecidos neoplásicos, e são mais rapidamente eliminados do sangue. A presente invenção também se relacionando a um método para diagnóstico e a um método para tratamento de uma doença neoplásica ou uma infecção por microrganismos em um mamífero, que compreende (a) exposição do mamífero a um período de dieta livre de vitamina B12, e (b) subseqüentemente aplicação de um derivado da cobalamina da presente invenção transportando um agente de diagnóstico e/ou agente terapêutico. Selecionando derivados da cobalamina que atuam como substituintes da vitamina B12, o risco de formação de uma descendência resistente de tecido neoplásico é muito reduzido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03405913 | 2003-12-22 | ||
| PCT/EP2004/053628 WO2005061527A1 (en) | 2003-12-22 | 2004-12-21 | Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0418010A true BRPI0418010A (pt) | 2007-04-17 |
Family
ID=34707293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418010-0A BRPI0418010A (pt) | 2003-12-22 | 2004-12-21 | derivados da cobalamina úteis para diagnóstico e tratamento de proliferação celular anormal |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7585852B2 (pt) |
| EP (1) | EP1697397A1 (pt) |
| JP (1) | JP4927560B2 (pt) |
| KR (1) | KR101126138B1 (pt) |
| CN (1) | CN1902214A (pt) |
| AU (1) | AU2004303528B2 (pt) |
| BR (1) | BRPI0418010A (pt) |
| CA (1) | CA2550657A1 (pt) |
| IL (1) | IL176415A (pt) |
| NZ (1) | NZ548009A (pt) |
| RU (1) | RU2394042C2 (pt) |
| WO (1) | WO2005061527A1 (pt) |
| ZA (1) | ZA200605079B (pt) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1457027A (en) * | 1974-05-10 | 1976-12-01 | Radiochemical Centre Ltd | Radioactively labelled vitamin b12 |
| US4209614A (en) * | 1978-05-30 | 1980-06-24 | E. R. Squibb & Sons, Inc. | Vitamin B12 derivative suitable for radiolabeling |
| HU183192B (en) * | 1980-07-30 | 1984-04-28 | Richter Gedeon Vegyeszet | Improved process for preparing corrinoide derivatives bearing a substituent in position co-aeta |
| DE3262956D1 (en) * | 1981-06-22 | 1985-05-15 | Technicon Instr | Labelled vitamin b12 derivatives, their preparation and use |
| CA1339491C (en) * | 1988-09-26 | 1997-10-07 | Say-Jong Law | Nucleophilic polysubstituted aryl acridinium ester and uses thereof |
| DE3900648A1 (de) * | 1989-01-11 | 1990-07-12 | Boehringer Mannheim Gmbh | Neue cobalamin-saeurehydrazide und davon abgeleitete cobalamin-konjugate |
| DE69528523T2 (de) * | 1994-04-08 | 2003-06-12 | Receptagen Corp., Edmonds | Rezeptor modulierendes mitteln und entsprechendes verfahren |
| US5739313A (en) * | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| AUPP405098A0 (en) * | 1998-06-12 | 1998-07-02 | Access Pharmaceuticals Australia Pty Limited | Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals |
| JP2002542207A (ja) * | 1999-04-16 | 2002-12-10 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 抗腫瘍剤として有用なコバラミンコンジュゲート |
| AU4243400A (en) * | 1999-10-15 | 2001-04-30 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging agents and as antitumor agents |
| AU785505B2 (en) * | 1999-10-15 | 2009-02-26 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| US6797521B2 (en) * | 1999-10-26 | 2004-09-28 | University Of Utah Research Foundation | Fluorescent cobalamins and uses thereof |
| JP5350570B2 (ja) * | 1999-10-26 | 2013-11-27 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 蛍光性コバラミンおよびその使用 |
| WO2002042318A2 (en) * | 2000-10-25 | 2002-05-30 | Mayo Foundation For Medical Education And Research | Transcobalamin receptor binding conjugates for neutron capture therapy |
| EP1435973A4 (en) * | 2001-09-28 | 2007-05-02 | Mayo Foundation | SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS |
-
2004
- 2004-12-21 BR BRPI0418010-0A patent/BRPI0418010A/pt not_active IP Right Cessation
- 2004-12-21 KR KR1020067012269A patent/KR101126138B1/ko not_active Expired - Fee Related
- 2004-12-21 CN CNA2004800382782A patent/CN1902214A/zh active Pending
- 2004-12-21 US US10/583,760 patent/US7585852B2/en not_active Expired - Fee Related
- 2004-12-21 JP JP2006546174A patent/JP4927560B2/ja not_active Expired - Fee Related
- 2004-12-21 RU RU2006126542/04A patent/RU2394042C2/ru not_active IP Right Cessation
- 2004-12-21 CA CA002550657A patent/CA2550657A1/en not_active Abandoned
- 2004-12-21 WO PCT/EP2004/053628 patent/WO2005061527A1/en not_active Ceased
- 2004-12-21 EP EP04804963A patent/EP1697397A1/en not_active Withdrawn
- 2004-12-21 NZ NZ548009A patent/NZ548009A/en not_active IP Right Cessation
- 2004-12-21 AU AU2004303528A patent/AU2004303528B2/en not_active Ceased
-
2006
- 2006-06-19 IL IL176415A patent/IL176415A/en not_active IP Right Cessation
- 2006-06-20 ZA ZA200605079A patent/ZA200605079B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7585852B2 (en) | 2009-09-08 |
| JP2007515457A (ja) | 2007-06-14 |
| WO2005061527A9 (en) | 2006-10-05 |
| RU2006126542A (ru) | 2008-01-27 |
| JP4927560B2 (ja) | 2012-05-09 |
| KR101126138B1 (ko) | 2012-04-12 |
| ZA200605079B (en) | 2007-12-27 |
| EP1697397A1 (en) | 2006-09-06 |
| KR20060121217A (ko) | 2006-11-28 |
| IL176415A0 (en) | 2006-10-05 |
| AU2004303528A1 (en) | 2005-07-07 |
| CA2550657A1 (en) | 2005-07-07 |
| RU2394042C2 (ru) | 2010-07-10 |
| NZ548009A (en) | 2010-03-26 |
| AU2004303528B2 (en) | 2009-05-28 |
| CN1902214A (zh) | 2007-01-24 |
| WO2005061527A1 (en) | 2005-07-07 |
| IL176415A (en) | 2011-03-31 |
| US20070155692A1 (en) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120977T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
| ES2162942T3 (es) | Nuevos derivados de acidos carboxilicos, su obtencion y empleo. | |
| NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
| BR9914044A (pt) | ésteres tetrahidropirido | |
| BRPI0408256A (pt) | composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| BR9714523A (pt) | Tratamento de nefrite de lúpus com compostos anti-cd40l | |
| BR0107157A (pt) | Diagnose e tratamento de condições cardiovasculares | |
| WO2022104136A3 (en) | Methods and compositions for tauopathy diagnosis and treatment | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| BRPI0513513A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente | |
| DK0969822T3 (da) | Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster | |
| PT1124841E (pt) | Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem | |
| EP1427418A4 (en) | PIPERAZINONE COMPOUNDS AS ANTITUMOROUS AND CANCER-COMBINING MEDICAMENTS AND TREATMENT PROCEDURES | |
| BR0001794A (pt) | Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares) | |
| Hubler et al. | Palliative irradiation of Scottish Fold osteochondrodysplasia | |
| NO20061184L (no) | Fremgangsmater og blandinger for behandling av herpes-infeksjoner | |
| Dörr | Effects of selenium on radiation responses of tumor cells and tissue | |
| BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| Harstrick et al. | A phase I dose escalation trial of intravenous treosulfan in refractory cancer | |
| BRPI0418010A (pt) | derivados da cobalamina úteis para diagnóstico e tratamento de proliferação celular anormal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |